Related Experiment Video

Updated: Aug 9, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.6K

SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers

Jie Mei1,2,3, Ziyi Fu2, Yun Cai3

  • 1Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, No. 299 Qingyang Road, Wuxi 214023, China.

Iscience
|February 23, 2023
PubMed

Insights

Secreted and transmembrane 1 (SECTM1) shows promise as a biomarker for predicting patient response to immune checkpoint inhibitors (ICIs) in cancer. Higher SECTM1 levels correlate with better immunotherapy outcomes across various cancer types.

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
  • Many patients do not respond to ICIs, necessitating predictive biomarkers.
  • Identifying reliable biomarkers is crucial for optimizing cancer immunotherapy.

Purpose of the Study:

  • To investigate the predictive value of secreted and transmembrane 1 (SECTM1) in cancer immunotherapy.
  • To explore the immunological correlations of SECTM1 expression in various cancers.
  • To assess SECTM1 as a potential biomarker for predicting response to ICIs.

Main Methods:

  • Analysis of SECTM1 expression in multiple public and in-house cancer cohorts.
  • Correlation analysis of SECTM1 with immunotherapeutic response and tumor immune status.
  • In vitro assays to investigate SECTM1 regulation by IFN-γ/STAT1 signaling.
  • Evaluation of tumor-expressed and circulating SECTM1 in immunotherapy cohorts.

Main Results:

  • SECTM1 expression was elevated in tumors from patients with favorable responses to immunotherapy across diverse cancers.
  • SECTM1 demonstrated pan-cancer immuno-correlation and was enriched in immune-hot tumors.
  • In vitro studies confirmed SECTM1 upregulation via the IFN-γ/STAT1 pathway.
  • Both tumor and circulating SECTM1 levels were identified as potential predictors of immunotherapy response.

Conclusions:

  • SECTM1 serves as a promising biomarker for predicting benefit from immune checkpoint inhibitors in cancer patients.
  • SECTM1's association with favorable immune responses highlights its role in immunotherapy.
  • Further large-scale studies are warranted to validate SECTM1 for clinical application as an ICI biomarker.
Keywords:
Bioinformatic numerical analysisBioinformaticsBiological sciencesGenomics

More Related Videos

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.2K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.7K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
612
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K